“Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis”, J of Skin, vol. 4, no. 6, p. s72, Oct. 2020, doi: 10.25251/skin.4.supp.72.